Table 2.

Antidrug antibodies

Measure	Overall ADA analysis population (n = 28)
Baseline test result, n (%)
Positive	2 (7)
Negative	26 (93)
Test result during treatment, n (%)
Positive	12 (43)
Positive but negative at baseline	10 (36)
Time to positivity in participants negative at baseline, weeks
Mean (SD)	3.6 (1.0)
Median	4.1
Min–max	2.0–4.4
Duration of positivity in participants negative at baseline, weeks
Median	4.1
Min, max	0.14+, 31.14+
Participants who were negative at baseline, had a positive postbaseline test, and had ≥1 subsequent test result, n (%)
Data available	9 (32)
All subsequent test results were negative	3 (11)
≥1 subsequent test result was positive	6 (21)
Last test was positive	4 (14)
Last test was negative	2 (7)

Abbreviation: ADA, antidrug antibodies.